Loading patent…
AssigneeHeidelberg Pharma Research GmbH
InventorsCharlotte Fenton McDonagh, Rajiv Panwar, Torsten Hechler, Michael Kulke, Ganapathy N. Sarma, Andreas Pahl, Christoph Mueller, Werner Simon, Christian Lutz, Francesca Gallo
Estimating the term…
Amatoxins, as well as antibody-drug conjugates (ADCs) comprising an amatoxin are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can be used for cancer therapy. They can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, as well as prevention of graft-versus-host-disease (GVHD), are provided.
An amatoxin comprising the structure of Formula (A) (HDP 30.2867):
An antibody-drug conjugate (ADC) comprising an antibody, or an antigen-binding fragment thereof, conjugated to an amatoxin via a linker, the ADC having the structure of Formula (Ia):
An antibody drug conjugate (ADC) comprising an antibody, or an antigen-binding fragment thereof, conjugated to an amatoxin via a linker, the ADC having the structure of Formula (IIa):
An antibody-drug conjugate (ADC), wherein the antibody-drug conjugate comprises an antibody, or an antigen-binding fragment thereof, which specifically binds to human PSMA, and comprises a heavy chain having an amino acid sequence according to SEQ ID NO. 374 and a light chain having an amino acid sequence according to SEQ ID NO. 376, and which is conjugated to compound HDP30.2867.
Dependencies are inferred from the claim text.